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E-mail address: araki@ncnp.go.jp (W. Araki).b-Amyloid peptide (Ab) is generated via sequential proteolysis of amyloid precursor protein (APP) by
b- and c-secretases. Cell-based screening experiments disclosed that the MEK (MAP kinase kinase)
inhibitors, U0126 and PD184352, suppress Ab secretion from human neuronal SH-SY5Y cells express-
ing Swedish mutant APP. These inhibitors did not affect the cellular levels of APP but signiﬁcantly
reduced those of the APP b-C-terminal fragment (b-CTF). Additionally, b-CTF levels were markedly
reduced by these inhibitors in cells expressing the fragment in a c-secretase-independent and pro-
teasome-dependent manner. Our results suggest that MEK inhibitors reduce Ab generation via
secretase-independent alteration of b-CTF levels.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is the most common neurodegenera-
tive dementia disorder pathologically characterized by neuronal
loss and formation of senile plaques and neuroﬁbrillary tangles.
b-Amyloid peptide (Ab), the main constituent of senile plaques, is
a major causative factor in AD pathogenesis according to the ‘‘amy-
loid cascade hypothesis”, and thus an important therapeutic target
[1]. Ab is generated via sequential proteolysis of amyloid precursor
protein (APP) by b-secretase (b-site APP cleaving enzyme 1:
BACE1) and c-secretase, which are recognized key proteases in
amyloidogenic processing [2,3].
The mechanisms underlying the regulation of Ab production
have yet to be fully elucidated, in part because several factors other
than secretases are also involved in Ab generation. In this regard,
Ab production is modulated via both secretase-dependent and -
independent mechanisms. For example, we recently reported that
insulin-like growth factor-1 (IGF-1) promotes Ab production via achemical Societies. Published by E
yloid peptide; APP, amyloid
l fragment; swAPP, Swedishsecretase-independent mechanism involving APP phosphorylation
at Thr668 [4]. One approach to resolving this issue is to test the
ability of various kinase inhibitors to modulate Ab production,
since protein phosphorylation is critical in the modiﬁcation of
intracellular signaling.
The present study was undertaken to uncover novel mecha-
nism(s) underlying the regulation of Ab generation. Accordingly,
we screened kinase inhibitor(s) able to modulate Ab production
using a cell-based assay employing human neuronal cells. Our data
show that MEK inhibitors exert an Ab suppression effect via a
mechanism involving secretase-independent alteration of the APP
b-C-terminal fragment (b-CTF) level.2. Materials and methods
2.1. Cell culture and transfection
Human neuroblastoma SH-SY5Y cells stably expressing Swed-
ish mutant APP (swAPP) or APP b-CTF (designated SH-swAPP and
SH-b-CTF, respectively) were established in previous studies
[4,5]. Cells were maintained in a humidiﬁed atmosphere of 5%
CO2/95% air in growth medium (DMEM/F12 supplemented with
10% fetal bovine serum) containing 200 lg/ml G418.lsevier B.V. All rights reserved.
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A rabbit polyclonal antibody speciﬁc for the C-terminus of APP
employed in this study is described in a previous report [6]. A rab-
bit polyclonal antibody (P-Thr668 antibody) speciﬁc for the
Thr668-phosphorylated APP (P-APP) was obtained from Cell Sig-
naling Technology (Beverly, MA, USA) while a rabbit polyclonal
antibody against BACE1 and mouse monoclonal antibody against
b-actin were purchased from Chemicon (Temecula, CA, USA) and
Sigma (St. Louis, MO, USA), respectively. PD184352, N-[N-(3,5-
diﬂuorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester
(DAPT) and chloroquine were obtained from Alexis (San Diego,
CA, USA), Calbiochem (San Diego, CA, USA) and Sigma, respectively.
U0126, U0124 and Epoxomycin were acquired from Wako (Osaka,
Japan). Kinase inhibitors used for screening (as listed in Supple-
mentary Table 1) were provided by the Screening Committee of
Anticancer Drugs supported by a Grant-in-Aid for Scientiﬁc Re-
search on Priority Area ‘‘Cancer” from MEXT (Japan).
2.3. Screening of kinase inhibitors that modulate Ab production
SH-swAPP cells were plated at a density of 2  105 cells/well on
a 24-well plate. One day after plating, cells were incubated with
growth medium containing each of the kinase inhibitors at 1 lM
for 24 h. Ab40 levels in the conditioned media were measured
using sandwich ELISA, as described below.
2.4. Western blot analysis
Western blot analyses were performed as described previously
[4,5,7]. Cells were lysed in RIPA buffer with protease inhibitors [7].
Proteins were separated on polyacrylamide gels, and blotted onto
polyvinylidene diﬂuoride (PVDF) membranes. Membranes were
treated with PBS containing 0.05% Tween-20 and 5% non-fat dry
milk to block non-speciﬁc binding sites, followed by probing with
the appropriate antibodies. Membranes were subsequently incu-
bated with anti-rabbit or anti-mouse IgG secondary antibodies
conjugated to horseradish peroxidase. Immunoreactive proteins
were detected with chemiluminescence reagents (PerkinElmer,
Boston, MA, USA). Densitometry was performed for quantitative
measurement of protein expression intensity with an image ana-
lyzer, LAS-1000 (Fuji Film Co., Tokyo, Japan).
2.5. Ab measurements
The concentrations of Ab40 and Ab42 in conditioned media
were measured essentially as described previously using sandwich
ELISA kits (Wako or IBL, Gumma, Japan) [4,5,8].
2.6. Statistical analysis
Statistical analyses were performed with one-way ANOVA, fol-
lowed by Bonferroni multiple comparison test or Student’s t-test.3. Results
In the present screening experiments, we employed human
neuroblastoma SH-SY5Y cells stably expressing swAPP (SH-swAPP
cells) that secrete large amounts of Ab40 and Ab42 [4,5]. SH-swAPP
cells were treated for 1 day with 110 different kinase inhibitors
listed in Supplementary Table 1 (ﬁnal concentration of 1 lM),
and the amounts of secreted Ab40 in the conditioned media as-
sayed using sandwich ELISA. Screening data revealed that a
MEK1/2 (MEK: MAP kinase kinase) inhibitor, U0126 [9] has a po-
tent Ab suppression effect. The other inhibitors that signiﬁcantlylowered Ab secretion included IKK-2 inhibitor VI, but we focused
on U0126 in this study. At concentrations of 1 and 2 lM, U0126 in-
duced a signiﬁcant decrease in Ab40 and Ab42 secretion by 40%
and 45%, respectively, compared to that in untreated control cells
(Fig. 1A). In contrast, U0124, an inactive analogue of U0126, had no
effect on Ab secretion (Fig. 1A). The MEK1/2 inhibitor, PD184352 (1
and 2 lM), with a chemical structure unrelated to that of U0126
[10], similarly reduced secretion of Ab from SH-swAPP cells
(Fig. 1A). U0126 and PD184352 also reduced Ab secretion by
14% and 31% at 0.25 lM, by 17% and 33% at 0.5 lM, and
by 50% and 50% at 5 lM, respectively (data not shown), sug-
gesting that PD184352 suppresses Ab secretion more potently than
U0126. Another MEK inhibitor, PD98059, did not clearly affect Ab
secretion at a concentration of 1 lM, but induced signiﬁcant de-
creases (by 30% and 35%) at 5 (data not shown) and 10 lM
(Fig. 1A), respectively.
We analyzed MEK-dependent phosphorylation of ERK by Wes-
tern blot analysis using an anti-phospho-ERK [9]. MEK-dependent
ERK phosphorylation was signiﬁcantly inhibited in SH-swAPP cells
treated with U0126, PD184352, or PD98059, but not in cells trea-
ted with U0124, conﬁrming the inhibition of intracellular MEK
activity. PD184352 exhibited the most potent inhibitory effect on
MEK (Supplementary data).
We employed U0126 and PD184352 for further analyses be-
cause of their potent Ab suppression effect. Western blot analysis
of cell lysates revealed that U0126 and PD184352 did not affect
the cellular levels of APP and BACE1, but signiﬁcantly suppressed
those of b-CTF of APP (by 40%) (Fig. 1B and C), compared to con-
trol cells. Marginal decreases in a-C-terminal fragment (a-CTF)
levels were observed in cells treated with the MEK inhibitors
(Fig. 1B and C). Additionally, these MEK inhibitors did not appear
to alter APP phosphorylation at Thr668 (Fig. 1B).
Next, we investigated the mechanisms underlying the MEK
inhibitor-induced decrease in b-CTF levels and Ab production,
using SH-SY5Y cells expressing b-CTF (SH-b-CTF cells) [4]. The b-
CTF levels were signiﬁcantly reduced in cells treated with U0126
or PD184352, compared with those in control cells (Fig. 2A and
B). These inhibitors additionally suppressed Ab40 secretion
(Fig. 2C). As b-CTF-expressing cells secrete small amounts of Ab,
the Ab42 levels were below the detection limit [4]. Our data sug-
gest that the Ab suppression effect of MEK inhibitors does not de-
pend on b-secretase processing of APP.
To clarify whether the inhibitory effects of the MEK inhibitors
on APP CTF and Ab production are dependent on c-secretase
processing of APP, we employed a well-known c-secretase inhibi-
tor, DAPT [11]. DAPT treatment of b-CTF-expressing cells aug-
mented the levels of b-CTF and a-CTF, the latter most likely
representing endogenous a-CTF. Interestingly, both U0126 and
PD184352 induced a signiﬁcant decrease in the b-CTF level, even
in the presence of DAPT (Fig. 3A and B), suggesting that these
agents decrease b-CTF levels through c-secretase-independent
mechanisms.
MEK inhibitors suppress the b-CTF level via a mechanism that
does not directly involve b- and c-secretases. This decrease in
availability of b-CTF, a c-secretase substrate, in turn leads to re-
duced Ab secretion. We hypothesized that MEK inhibitors affect
secretase-independent degradation of b-CTF. To conﬁrm this the-
ory, we performed experiments with chloroquine, an agent that
disrupts lysosomal function, and epoxomycin, a speciﬁc protea-
some inhibitor. Upon treatment of SH-b-CTF cells with U0126 or
PD184352 in the presence of chloroquine, b-CTF levels were effec-
tively reduced, compared to those in cells treated with chloroquine
alone (Fig. 4A and B), suggesting that the lysosomal system is not
involved in the MEK-inhibitor-induced reduction of b-CTF levels.
Interestingly, a-CTF levels were augmented in chloroquine-treated
cells (Fig. 4A), which may be attributed to inhibition of lysosomal
Fig. 1. MEK inhibitors exert an Ab suppression effect in neuronal cells expressing swAPP. (A) SH-swAPP cells were seeded into 12-well plates at a density of 5  105 cells/well,
and incubated without or with the indicated concentrations of U0126, PD184352, PD98059, or U0124 for 24 h. The amounts of Ab40 and Ab42 in conditioned media were
quantiﬁed using sandwich ELISA. The mean amounts of Ab40 and Ab42 in control cells were 2.83 and 0.52 pmol/mL. (B) Western blot analysis of lysates of cells treated with
the indicated concentrations of U0126 (U) or PD184352 (PD) for 24 h. The membrane was probed with antibodies against APP, P-APP, BACE1, and b-actin. For analysis of APP
CTFs, proteins were separated on Tris/Tricine gels. (C) Band intensities in (B) were quantiﬁed by densitometric analysis, and the relative expression levels of b-CTF and a-CTF
calculated. Data are presented as mean values ± S.E.M. from three independent experiments. *P < 0.01, compared to control.
Fig. 2. Effects of MEK inhibitors on b-CTF levels and Ab production in neuronal cells expressing b-CTF. (A) SH-b-CTF cells were treated without or with U0126 or PD184352
(2 lM) for 24 h, followed by Western blot analysis with the APP antibody. (B) Band intensities in (A) were quantiﬁed, and the relative expression levels of b-CTF calculated.
Data are presented as means ± S.E.M. of four independent experiments. *P < 0.01, compared to control. (C) ELISA analysis of secreted Ab40 from cells treated as in (A). The
mean amount of Ab40 in control cells was 12 fmol/mL. Data are presented as mean values ± S.E.M. of duplicate experiments.
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observation that a-CTF similarly accumulates in untransfected SH-
SY5Y cells treated with chloroquine (data not shown). The reduc-
tion in b-CTF levels was repressed upon co-treatment of cells witheach of the MEK inhibitors and epoxomycin, compared to cells
treated with epoxomycin alone (Fig. 4C and D). In addition, another
proteasome inhibitor lactacystin (3 or 5 lM) also signiﬁcantly
inhibited the U0126 induced reduction in b-CTF levels (data not
Fig. 3. MEK inhibitors decrease b-CTF levels in the presence of a c-secretase
inhibitor. (A) SH-b-CTF cells were pretreated with 0.5 lM DAPT for 2 h, followed by
treatment with or without U0126 or PD184352 (2 lM) in the presence of DAPT for
24 h. Cell lysates were subjected to Western blot analysis, as described for Fig. 2. (B)
Band intensities in (A) were quantiﬁed, and the relative expression levels of b-CTF
calculated. Data are presented as mean values ± S.E.M. from three independent
experiments. *P < 0.05, compared to cells treated with DAPT alone.
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in the reduction of b-CTF levels and Ab secretion induced by MEK
inhibitors.
4. Discussion
The present screening study shows that the MEK inhibitors,
U0126 and PD184352, exert a potent Ab suppression effect in
SH-swAPP cells. Western blot analysis of these cell lysates revealed
that the MEK inhibitors induce a signiﬁcant reduction in b-CTF lev-
els. MEK inhibitors additionally lower b-CTF levels in SH-b-CTFFig. 4. The proteasomal pathway is involved in the reduction of b-CTF levels induced by M
followed by treatment with or without U0126 or PD184352 (1 lM) in the presence of chl
for Fig. 2. (B) Band intensities in (A) were quantiﬁed, and relative expression levels of
independent experiments. *P < 0.01, compared to cells treated with chloroquine alone. (C
without or with U0126 or PD184352 (1 lM) in the presence of epoxomycin for 24 h. Ce
relative expression levels of b-CTF presented as a graph. Data are presented as mean vacells, which are unaffected by the c-secretase inhibitor, DAPT.
These ﬁndings indicate that the MEK inhibitors exert an Ab sup-
pression effect independently of b- and c-secretases via a mecha-
nism involving the alteration of b-CTF levels.
It is possible that MEK inhibitors affect APP CTF levels by
altering phosphorylation at Thr668, since this process is critically
involved in the regulation of APP CTF levels [4,12]. However, in
our experiments, MEK inhibitors did not alter APP phosphoryla-
tion at Thr668. The inhibitory effects of these agents on b-CTF
levels were suppressed upon co-treatment with a proteasome
inhibitor, epoxomycin, but not the lysosomotropic agent, chloro-
quine. We propose that MEK inhibitors possibly induce a de-
crease in the availability of b-CTF by facilitating its proteasomal
degradation, consequently leading to reduced Ab production. This
theory is consistent with previous reports showing that b-CTF is
degraded via a proteasome-dependent mechanism [13]. However,
the precise relationship between inhibition of MEK and proteaso-
mal degradation of b-CTF remains to be determined. Nonetheless,
these ﬁndings provide important insights into the secretase-inde-
pendent regulation of b-CTF levels and Ab generation in neuronal
cells.
Upon treatment of SH-b-CTF cells with chloroquine, there was
no increase in b-CTF-levels, whereas a-CTF levels were augmented.
This suggests that a-CTF, but not b-CTF, is normally subjected to
lysosomal degradation. Treatment of SH-b-CTF cells with epoxo-
mycin did not increase b-CTF levels. The reason for this is not clear,
but may be related to the cellular toxicity of epoxomycin.
Our data suggest that MEK inhibitors have therapeutic potential
against AD. In this context, it would be of interest to establish
whether these inhibitors negatively modulate Ab production
in vivo with the aid of animal AD models, such as APP transgenic
mice. Notably, inhibitors of various protein kinases are potential
candidate drugs for the treatment of central nervous system disor-
ders [14], and inhibition of MEK1/2 with U0126 or SL327 (an ana-
logue of U0126) results in neuroprotection against ischemic brain
injury [15,16]. Thus, while inhibitors of b-secretase and c-secretase
are promising candidates as mechanism-based therapeutics, other
agents that inhibit Ab production independently of b- and c-secre-
tases may also have potential efﬁcacy in the treatment and preven-
tion of AD.EK inhibitors. (A) SH-b-CTF cells were pretreated with 100 lM chloroquine for 6 h,
oroquine (Chl) for 24 h. Cell lysates were analyzed by Western blotting, as described
b-CTF presented as a graph. Data are presented as mean values ± S.E.M. of three
) SH-b-CTF cells were pretreated with 50 nM epoxomycin (Epo) for 6 h, and treated
ll lysates were analyzed as in (A). (D) Band intensities in (C) were quantiﬁed, and
lues ± S.E.M. of three separate experiments.
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